OncLive® On Air

In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a genitourinary medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, sits down with Tejas Patil, MD, an assistant professor of medicine-medical oncology at the University of Colorado School of Medicine - Anschutz Medical Campus in Aurora.In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial (NCT03521154), where treatment with osimertinib (Tagrisso) following definitive chemoradiotherapy led to an improvement in progression-free survival vs placebo in patients with stage III, EGFR-mutated non–small cell lung cancer (NSCLC).Drs Park and Patil also explore the implications of minimal residual disease (MRD) monitoring in the phase 3 ADAURA trial (NCT02511106) and how liquid biopsy data may influence future treatment timelines. Additionally, they delve into the evolving role of osimertinib in advanced EGFR-mutated NSCLC, based on results from the phase 3 FLAURA2 trial (NCT04035486) and its potential impact on the treatment of patients with brain metastases.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner. OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, supported by AbbVie, we had the pleasure of speaking with Jennifer Crombie, MD, about the FDA approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma. Dr Crombie is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts.On June 26, 2024, the FDA granted accelerated approval to epcoritamab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. This regulatory decision was supported by findings form the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which the agent yielded an overall response rate of 82% (95% CI, 74.1%-88.2%) in the primary efficacy cohort (n = 127), including a complete response rate of 60% (95% CI, 50.8%-68.4%). In our exclusive interview, Dr Crombie discussed the significance of this approval, key findings from the pivotal EPCORE NHL-1 trial, and where the future of the FL treatment paradigm is headed. ___That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AbbVie. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

In today’s episode, we invited experts from across oncology specialties to discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress. Emre Yekedüz, MD, an associate professor of medical oncology at Ankara University in Turkey and a research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts, shared insights on his latest work in gastrointestinal malignancies, particularly in pancreatic and colorectal cancer. Thach-Giao Truong, MD, a hematologist and medical oncologist at the Cleveland Clinic in Ohio who specializes in skin cancers including basal cell carcinoma, melanoma, and Merkel cell carcinoma, highlighted her recent findings in targeted therapies for advanced skin cancers. John H. Strickler, MD, an associate professor of medicine in the Division of Medical Oncology at Duke University in Durham, North Carolina, emphasized key updates in the treatment of gastroesophageal malignancies, where he sees significant progress on the horizon. David Spigel, MD, chief scientific officer and medical oncologist at Sarah Cannon Research Institute in Nashville, Tennessee, discussed the expanding clinical trial program he oversees, ensuring patients have access to cutting-edge therapies. Finally, Paolo Tarantino, MD, a researcher at the European Institute of Oncology and clinical research fellow at Dana-Farber Cancer Institute, focused on advancements in breast cancer research, particularly in HER2-targeted therapies and antibody-drug conjugates.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a review session for the oncology board exams. Drs Armstrong and Tawagi discussed high-yield oncology and hematology topics to focus on during study sessions, memorization tricks they used for their own boards, and other tips for exam preparation.

In today’s episode, we had the pleasure of speaking with Narjust Florez, MD, about patient-focused lung cancer biomarker testing discussions.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.

Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.

Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma.

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.

Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.

OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.

Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.

Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.

Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.

Dr Rosenberg discusses current standard strategies for treating patients with nasopharyngeal cancer, the evolving role of toripalimab in this treatment paradigm, and how future advances in nasopharyngeal cancer management may impact the head and neck cancer treatment paradigm more broadly.

OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.

Dr Paik discusses key findings from the phase 2 VISION trial investigating frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping alterations, real-world data from the TOGETHER pooled analysis of tepotinib vs other frontline treatment options in this patient population, and insights regarding treatment sequencing with tepotinib in pretreated patients in this population.

Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.

Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed.

Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, their advice for monitoring and managing treatment-related toxicities with this combination, and more.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.

Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.

Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and more.

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.

Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.